Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023.
Marta BassiDaniele FranzoneFrancesca DufourMarina Francesca StratiMarta ScalasGiacomo TantariConcetta AloiAlessandro SalinaGiuseppe d'AnnunzioMohamad MaghnieNicola MinutoPublished in: Life (Basel, Switzerland) (2023)
Type 1 diabetes (T1D) patients' lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems' efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.
Keyphrases
- type diabetes
- glycemic control
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- cardiovascular disease
- pregnant women
- ejection fraction
- public health
- metabolic syndrome
- peritoneal dialysis
- prognostic factors
- physical activity
- deep learning
- mental health
- machine learning
- social media
- risk assessment
- climate change
- data analysis
- big data
- case control